Abiraterone acetate (Zytiga®) for mHSPC

Assessment Status No HTA dossier submitted
Drug Abiraterone acetate
Brand Zytiga®
Indication Treatment of newly diagnosed high-risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT).
Assessment Process
Rapid review commissioned 03/10/2018
Rapid review completed 15/11/2018
Rapid review outcome Full Pharmacoeconomic Assessment Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.